The alpha chain of the interleukin 2 receptor (IL2R␣; Tac) was targeted in clinical trials with adult T cell leukemia using murine anti-Tac antibody. Of 19 patients, a single individual achieved a durable complete remission. The mechanism of this action by murine anti-Tac has not been defined. We examined the hypothesis that the maintenance of the long-term response after treatment might be related to induction of a network of anti-idiotypic antibodies, as proposed in other tumor settings. In contrast to anti-Tac non-responders, the patient was found to have produced a human anti-mouse antibody (HAMA) response, and specifically an anti-idiotypic ( 
Introduction
The alpha chain of the interleukin 2 receptor (IL2R␣, Tac, CD25) has been identified as a target for antibody-based immunotherapy in malignancy and immune disease.
1,2 The prototypical cancer for these studies has been adult T cell leukemia (ATL), based on the sustained, high expression of Tac on all malignant cells. This disorder is characterized by leukemic and lymphomatous components with infiltration of skin, liver, spleen and lungs, hypercalcemia, and immunosuppression with diminished or absent delayed type hypersensitivity (DTH) responses and reduced antibody responses to new antigens. The disorder is associated with HTLV-1 infection, with Ϸ2-5% of infected individuals developing the disease with a lag period of up to 20 years. 3 ATL is endemic in Japan, Southeast Asia, Equatorial Africa and the Caribbean Basin. When patients come to medical attention, survival is typically brief (median 3 months) and the disease is resistant to standard chemotherapeutic regimens. As a consequence, it has been acceptable to treat such patients de novo with experimental therapies. A cohort of 19 patients were treated with murine anti-Tac (MAT), a mouse monoclonal antibody against the Tac antigen, showing complete responses in two, partial responses in four and mixed response in one patient, for a total response rate of 37%. 4 One of these patients had a durable response following a single course of treatment over a 7-week period, and is now 8 years without evidence of recurrence.
The mechanism of action of anti-Tac has not been defined generally, or specifically, in the instance of this long-term remission. 4 All other patients with partial or complete remissions experienced relapse or disease recrudescence shortly after their initial responses, and all ultimately failed further treatment with the antibody. 4 The repeated use of murine monoclonal antibodies therapeutically may be limited by the development of human anti-mouse antibodies (HAMAs). 5, 6 Nevertheless, it was noted 4 that ATL patients who showed partial or complete remissions were more likely to have mounted HAMA responses; HAMAs were absent among non-responders, in accordance with the generalized immunosuppression associated with this disease. Accordingly, in the present study we examine the hypothesis that the maintenance of the single long-term remission after cessation of treatment might be related to the induction of HAMAs, and, specifically, induction of a network of anti-idiotypic antibodies, as proposed in other tumor settings.
HAMAs are predominantly formed against the constant domains of the mouse immunoglobulin, leading to a decrease in serum half-life. 5, 6 Anti-idiotypic antibodies (Ab2), which recognize the antigen binding site of the therapeutic antibody (Ab1), 7 may constitute a portion of this response. 8 The use of chimeric or humanized antibodies that substitute human for rodent constant domains reduces the incidence and intensity of HAMA responses, but the possibility of an anti-idiotypic response remains. [9] [10] [11] [12] Anti-idiotypic antibodies will directly block binding of the therapeutic antibody to the target antigen, and may thereby block the effectiveness of passive immunotherapy. 8, 13 The binding of Ab2 and antigen to sites on the Ab1 antibody may overlap, 14 allowing the Ab2 to mimic the antigen and bind to antigen ligands (eg Ab2 antibodies which develop after treatment with anti-Tac could bind to IL2) ( Figure 1 ). Furthermore, it was postulated the ('Jerne network hypothesis') that each anti-idiotype antibody may serve as the antigen for the next anti-idiotype along the cascade, yielding further anti-anti-idiotypic antibodies (Ab3, Ab4, etc) while also providing an activating stimulus for the B cell carrying the idiotype it recognises, thus generating an interacting network. 7 By this, the anti-anti-idiotypic Ab3, like Ab1, could potentially bind to the original antigen ( Figure 1) . 15 In this way, the antibody cascade could propagate and maintain internal images of the antigen and/or antibody in a persistent autogenic response. Accordingly, this model has been adapted to explain the correlation of the presence of Ab2
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Figure 1
Idiotype cascade showing reactivity with ligand and/or receptor by mirror image. A tumor cell displaying a cytokine receptor as a tumor-associated antigen is targeted with antibody (Ab1) that blocks the ligand binding site. The idiotype of this antibody elicits an anti-idiotype response with generation of Ab2 antibodies. A portion of the Ab2 may mimic receptor topology and also bind ligand. Idiotypes of the Ab2 may in turn elicit Ab3 antibodies. A portion of the Ab3 may mimic ligand topology and bind to receptor (antigen). In this example, Ab1 is a xenogeneic (mouse) antibody against the tumor antigen. Ab2 and Ab3 are endogenous, human antibody responses, by which an autogenic reaction against ligand and/or receptor may be maintained.
and Ab3 17, 18 antibodies with improved disease prognosis following immunotherapy with murine antibodies in some nonhematologic cancers. An analogous role for anti-Ab2 T cell responses in improved survival after antibody therapy has also been proposed. 19 In this report we examine retrospectively the possible role of anti-idiotypic network induction in the sole durable remission of an ATL patient treated with anti-Tac. The circulating HAMA response 4 years after cessation of treatment is analyzed and phage display technology is used to recapitulate the antibody repertoire 20, 21 of this anti-Tac-treated long-term survivor.
Materials and methods
Patient
The patient (CC) was a 65-year-old African American male who presented to the NIH Clinical Center with a diagnosis of acute phase ATL. The patient had circulating malignant Tac + cells of 30 000/l, massive hepatosplenomegaly, skin infiltration, hypercalcemia, soluble Tac level of 210 000 units/ml (normal range 250-502 units/ml), and an ECOG performance status of 2 with fatigue and malaise. Serology was positive for HTLV-1 antibodies. He was treated with seven 50 mg doses of MAT i.v. over a period of 2 months. Circulating Tac + cells declined gradually to normal levels over the 2 months of the treatment period and liver and spleen returned to normal dimensions. 4 The patient has been seen on an annual basis at the NIH without relapses.
Analysis of patient plasma for antibodies to the infused MAb Fifty milliliters of heparinized blood were obtained with the patient's informed consent at the 4-year point following therapy. Plasma was evaluated for MAT reactivity using a two arm radioimmunoassay as previously described. 22, 23 QuantAffinity beads were coated with 5 g/ml MAT in 0.8 M phosphate buffer pH 7 overnight at room temperature and washed three times in 4 ml of wash buffer (PBS 1% BSA 1 mM EDTA). Beads were blocked with PBS 3% BSA for 1 h at room temperature and incubated for 2 h on ice with 1:10 plasma dilutions in PBS 1% BSA, previously determined to be within the linear portion of the dose-response curve. Displacing antibody or purified sTac at 10 g/ml was included for cold competitions. Beads were washed three times with wash buffer and incubated with 200 l 125 I-labeled MAT at 0.1-0.2 g/ml in wash buffer for 30 min on ice. Beads were washed again, transferred to clean tubes and counted. This RIA is sensitive to 1 ng/ml of specific antibody.
Preparation of phage display libraries
PBLs were isolated from heparinized blood by Ficoll gradient centrifugation. RNA preparation from PBLs and PCR amplification of immunoglobulin light chains and heavy chain Fd fragments were as previously described. 24 Combinatorial antibody libraries were constructed using NPC3, a derivative of the pComb3 M13 25 surface phage display system (gift of C Barbas, Scripps Research Institute). Library construction was as described for the pComb3 system with the following modifications. PCR products from the V family-specific 5Ј primers were pooled for each heavy chain isotype (IgG1, IgM and IgD) and for the and light chains, and purified using Wizard PCR Clean-Up columns (Promega, Madison, WI, USA) prior to restriction digestion. Construction of Fab display libraries requires two ligation steps, insertion of amplified light chains followed by insertion of heavy chain Fd PCR products, to produce combinatorial heavy and light chain libraries. Since light chain PCR products may contain internal restriction sites which would interfere with subsequent heavy chain ligations, light chain PCR products were digested with the enzymes necessary for both ligation steps. Inserts were then gel purified on 2% agarose, electroeluted and purified using Wizard DNA Clean-Up columns. Inserts containing internal restriction sites no longer have compatible ends for ligation into the vector 984 and are lost from further steps in library preparation. After removal of stuffer fragments from NPC3 for light chain ligation, and from light chain libraries for heavy chain ligation, the vector/library was purified on Wizard DNA Columns (without gel purification).
Enrichment and isolation of antigen-specific phage Panning was carried out against antigen (MAT, HAT, UPC10 or sTac) bound to 96-well EIA/RIA plates as previously described. 24 Amplification of antigen-specific phage was monitored using the titre of eluted phage, and using ELISAs of both eluted libraries and randomly picked individual clones in combination with PCR screening to ensure presence of complete Fab clones. 26 Clones were selected from early rounds of panning to minimize competition between clones for plate-bound antigen during enrichment.
Sequencing and sequence analysis of Fab fragments
Sequencing to confirm CDR identity was carried out using cycle sequencing (Cycle Sequencing Kit; Pharmacia, Uppsala, Sweden) of PCR amplified heavy and light chain inserts and primers complementary to the IgG1 C H 1 domain (␥1rev 5Ј-cccagaggtgctcttggagga-3Ј) and chain constant region (rev 5Ј-tccagatttcaactgctcatc-3Ј). The complete sequence of the clone was obtained using Sequenase 2, the above primers and primers complementary to the leader sequences (LC for 5Ј-acagctatcgcgattgcagt-3Ј for the light chain and HC for 5Ј-tattactcgctgcccaacca-3Ј for the heavy chain). Sequences were then analyzed using SAW Version 1.4 software. 27 ELISA analysis of cc␣Id specificity ELISAs were performed as previously described. 26 After panning, eluted phage were infected into XL1 Blue (Stratagene, La Jolla, CA, USA). Individual phagemid colonies were picked from LB ampicillin plates and amplified by co-infection with helper phage (VCS M13; Stratagene) and overnight culture in selective media. E. coli were removed by centrifugation and the resulting phage containing supernatant used in ELISAs. Ninety-six-well EIA/RIA plates were coated with MAT, HAT or carrier-free IL2 (gift of G Ju, Hoffmann-La Roche) at 1 g/ml in 0.1 M carbonate buffer, pH 8.0, blocked with PBS 3% BSA and incubated with 25-50 l of phage (5 × 10 7 -5 × 10 8 c.f.u.) for 1 h at 37°C. After washing with PBS 0.05% Tween 20, plates were developed with biotinylated anti-M13 antibody (5 Prime 3 Prime, Boulder, CO, USA) followed by ExtraAvidinPeroxidase (Sigma, St Louis, MO, USA), both at 1:1000 in PBS 1% BSA. Color was developed using ABTS (2,2Ј-azino-bis(3-ethylbenzthiazoline-6-sulphonic acid)) in citrate buffer 0.01% H 2 O 2 and absorbance was read at 414 nm.
Purification and characterization of Fab fragment
The gene III coat protein was removed by restriction digestion and re-ligation. Fab fragment was purified by freeze/thaw lysis of bacterial pellets as previously reported 28 and chromatography on a murine anti-Tac affinity column prepared by coupling 0.5 ml of Affi-Gel 10 (BioRad, Hercules, CA, USA) to 1 mg of MAT. Purified Fab was dialysed against 0.1 M ammonium bicarbonate, lyophilised and resuspended in PBS. Fab was then size fractionated on a PD10 column (Pharmacia) and quantified by OD 260/280 . Purity was confirmed by gel electrophoresis. Affinity of the Fab clone for murine anti-Tac was evaluated using a bead-based radioimmunoassay. QuantAffinity beads were coated with MAT and blocked as described above for RIA of plasma. cc␣Id was labeled with 125 I using Iodobeads (Pierce, Rockford, IL, USA) per manufacturer's instructions to a specific activity of approximately 1 × 10 7 c.p.m./g. Labeled cc␣Id at various concentrations in PBS 1% BSA (200 l final volume) was incubated with MATcoated beads for 2 h on ice, washed and counted as for the plasma RIA above.
Evaluation of T3 response T cell response to antigen was performed as described for 3 and 6 day assays. 19, 29 Quantities for each antigen were: 5 and 50 g/ml for sTac, 20 g/ml for anti-Id and MAT. One assay was performed with sTac in the presence of four-fold molar excess of MAT to determine if MAT would block any proliferation of T cells induced by sTac. 29, 30 Positive control for T cell proliferation was provided by PHA at 1 g/ml. All assays were performed in triplicate in RPMI + 5% human AB serum.
Results
Analysis of patient plasma
To judge the persistence of the anti-globulin response in this patient, the reactivity to the antibody used in therapy, MAT, was assayed in plasma collected 4 years after treatment. Reactivity with MAT was detectable by RIA ( Figure 2 ). There was no plasma reactivity to UPC 10, an isotype control IgG2a, mouse myeloma protein, indicating that there is no detectable response against the constant domains of MAT. Furthermore, binding to MAT was not displaced by UPC 10, but MAT was displaced both by MAT and by humanized anti-Tac, HAT, which shares only the CDRs and six framework residues with MAT. 29, 31 ('cc␣Id' is discussed below.) The persistent HAMA response to MAT in this patient was therefore predominantly anti-idiotypic. In RIA assays using sTac-coated beads, no Tacbinding Ab3 antibodies were detected that could mimic the specificity of the therapeutic monoclonal antibody (data not shown).
Preparation of combinatorial libraries
To assess the diversity of the anti-idiotypic response, and as a more sensitive test for the presence of Ab3 antibodies, phage display libraries were prepared from the patient's PBLs ( Figure  3) . A total of six combinatorial Fab phage display libraries were prepared from PBL RNA, or light chains in combination with IgG1, IgM and IgD heavy chains. Each of these libraries had a diversity of 4 × 10 7 -2 × 10 8
. The diversity was defined as the number of phagemid colonies after heavy chain ligation and electroporation multiplied by the percentage of clones containing both heavy and light chain inserts as assessed by PCR of randomly picked colonies. 26 Heavy and light chains from randomly picked clones were PCR amplified, digested with BstN1 and run on high percentage agarose gels to confirm diversity of the libraries. After establishing the complexity of each separate library, the six libraries were then pooled to give equal representation of each.
Panning of combinatorial libraries
The resulting library pool was panned against four antigens to retrieve the response induced by the anti-Tac treatment: MAT to enrich for all HAMA antibodies, isotype control UPC 10 to enrich for antibodies against the constant domains, humanized anti-Tac (HAT) to select anti-idiotypic antibodies (Ab2), and sTac to select for Ab3 antibodies.
Panning against UPC 10 showed no selection for antigenspecific phage after five to six rounds of panning, and no phage specific for UPC 10 were detected by ELISA of Ͼ50 random clones after rounds 4, 5 and 6 of panning (total of Ͼ150 clones). As with the analysis of serum, we could find no evidence for a HAMA response against the constant domains of MAT.
Panning against both MAT and HAT showed enrichment after three to four rounds of panning, with Ͼ90% of the phage binding to both HAT and MAT by ELISA by the fifth round of panning, regardless of the panning antigen. More than 50 clones from rounds 3 and 4 of panning against MAT and HAT were assayed for antigen specificity by ELISA. All clones (Ͼ200 in total) were found to bind both HAT and MAT (approximately 50-90% of clones depending on the round of panning) or to bind to neither antigen (data not shown). Since HAT shares only the CDRs and a few (six) framework residues with MAT, all the MAT-reactive clones must be anti-idiotypic. Using phage display techniques, as found by RIA analysis of plasma, the HAMA response in this patient 4 years after treatment was found to be completely anti-idiotypic.
Despite extensive screening, no phage titer enrichment was observed when the library was panned against sTac. ELISA analysis of Ͼ200 random clones from rounds 4, 5 and 6 during panning showed no phage expressing sTac-specific antibodies. We therefore found no evidence for the presence of Ab3 anti-Tac antibodies, confirming the lack of plasma reactivity.
Sequence analysis of selected clones
The diversity of the anti-idiotypic response was analysed by sequencing 12 randomly selected MAT binding clones: six from panning against the murine antibody and six from panning against the humanized antibody. Using cycle sequencing of heavy and light chain inserts amplified by PCR, these were shown to have identical CDR3 sequences in both the heavy chain (IgG1) and light chain (). All clones sequenced were identical and the antibody was denoted 'cc␣Id'. The complete sequence of the variable domains of the Fab fragment, cc␣Id, is shown in Figure 4 . The light chain is from the Vk3 family and uses the Jk5 joining region; the heavy chain is from the Vh5 family and uses the Jh3e joining region. Both the light and heavy chain show high homology with germline genes. The light and heavy chain are mutated in 8 and 22 sites rela-
Figure 4
Sequence of cc␣Id and germline homology. Complete amino acid sequence of variable domains of cc␣Id. Closest germline homology is shown for comparison, hvk3g001 and Jk5 for the light chain and hvh5g001 and JH3a for the heavy chain, nomenclature as defined in SAW version 1.4. * Sequences dictated by vector and/or PCR primers. Region with homology to Tac is underscored.
tive to germline, yielding changes in 4 and 10 amino acids, respectively. Characteristically, a large segment of CDR3 of the heavy chain cannot be definitively paired with a specific germline D gene.
Central to the role of idiotypy in generating ligand-reactive Ab2 antibodies or antigen-reactive Ab3s that could participate in therapeutic responses is an implicit topological similarity between antigen and Ab2 idiotopes (the antigenic elements of the idiotype) (Figure 1 ). To address this question, the amino acid sequence of cc␣Id was compared with Tac by Lawrence homology search. 32 This revealed a short segment of homology between residues 47 and 51 of light chain at the junction of framework 2-CDR2 (Leu-Leu-Ile-Leu-Cys) (homology underlined) and residues 42-46 of Tac (Leu-Tyr-Met-Leu-Cys). Although the homology is limited (60% identity over five amino acids, s.d. score 2.6, P = 0.01), it is notable that this region in Tac overlaps with the proposed binding site for IL2. 33 Perhaps more significantly, this region of the otherwise germline light chain contains two amino acid changes, Tyr 50 →Leu and Gly 51 →Cys, both of which result in increased homology with Tac. It has been suggested that a single CDR loop may mimic a ligand or antigen, 34 and sequence homology with antigen of V H and V L CDR segments in an anti-idiotypic antibody have been noted previously. 35 Specificity and affinity of cc␣Id Displacement ELISA of cc␣Id Fab-phage confirmed that the Fab binds to the antigen binding site of MAT/HAT because: (1) cc␣Id phage bind to both HAT and MAT; (2) phage binding to either HAT or MAT is displaced by either HAT or MAT; and (3) phage binding to either HAT or MAT is displaced by sTac ( Figure 5 ). Less than quantitative displacement by ligand may be due to affinity-enhanced binding by phage that displays Ͼ monovalent Fab, particularly for sTac which can only bind monovalently. cc␣Id was prepared as soluble Fab for biochemical studies (Materials and methods). Purified cc␣Id Fab was shown to displace the majority of serum binding to MAT (Figure 2 ), confirming again that the dominant, persistent HAMA response is anti-idiotypic. Scatchard analysis of affinity-purified cc␣Id Fab showed a moderate affinity, monovalent Ka of 1.8 × 10 7 /m with MAT immobilized covalently on beads ( Figure 6 ).
An anti-idiotypic antibody which recognises the antigen binding site has the potential to act directly in the therapeutic setting. The Ab1 antibody, MAT, binds to the ␣ chain of the IL2 receptor (Tac) and can block IL2-dependent proliferation. 1, 29 In theory, the anti-idiotype may mimic epitope(s) on Tac and bind IL2 (Figure 1 ), leading to starvation of IL2-dependent cells. Limited homology of cc␣Id Ab2 with Tac was noted above. To examine this hypothesis in the present setting, cc␣Id was tested for IL2 binding by ELISA. No specific binding could be shown (data not shown), therefore excluding this as a potential mechanism for the observed clinical response.
Test of Ab2-induced T cell response
After completion of the foregoing studies, we became aware of work suggesting that Ab2 responses may in turn induce not only Ab3 but so-called T3 responses as well. 19 In this, the Ab2 idiotype presented in the context of MHC is recognized by T cells (T3) that by cross-reaction also recognize the original antigen in the context of MHC and lyse the antigen-expressing tumor cells. The domain of shared homology between Tac and anti-Id would provide such an opportunity. The T3 responses in that study 19 correlated with an improved survival, suggesting an etiologic role in disease remission. At 7 years post-therapy, we obtained blood from the patient and assayed for T cell proliferation induced by antigens: MAT (Ab1), antiId (Ab2) and Tac (antigen). In all instances, proliferation was not above background. This implied that there was no persistent T cell response to anti-Id (Ab2) or to Tac (antigen). Yet there was also no persistent response against MAT (Ab1), which had to be immunogenic to T cells at one time in this patient to have 'helped' the class-switched, IgG1 anti-Id
Figure 6
Scatchard analysis to determine affinity of cc␣Id for MAT. Results are averages of triplicates. Affinity was determined by linear regression.
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response observed in this patient. The negative data for the Ab1 T cell response suggests the time frame of out test was by now too late and the sensitivity of the assay too low to retrieve prior T cell memory activity related to the anti-Tac antibody therapy.
Discussion
Treatment of ATL patients with passive serotherapy with murine anti-Tac antibody resulted in an overall response rate of 37%. Mechanisms of response in antibody therapy have been proposed to include complement-dependent cytotoxicity (CDC), antibody-dependent cell-mediated cytotoxicity (ADCC), apoptosis, and receptor blockade for an essential cytokine. 36 CDC has generally been discounted as a factor for anti-tumor therapy in humans due to the relative inefficiency of IgG (relative to IgM) in complement fixation, plus the widespread expression of complement inactivating factors that protect against adventitious damage to autologous tissues. 36 Correspondingly, anti-Tac and human complement are inactive in CDC against ATL cell lines. 29 ADCC activity by in vitro tests was correlated with clinical activity in settings where isotypeswitched or human-mouse chimeric variants were studied (reviewed in Ref. 36 ). However, murine anti-Tac antibody is inert in ADCC 29 and clinical monitoring showed delayed clearance (over weeks) of malignant cells post-infusion of antibody 4 rather than the rapid clearance that normally accompanies effective opsonization. Anti-Tac suppresses IL2-dependent proliferation with activated T cells in vitro 29 and in organ transplant settings in vivo, 30 and is plausible as a means to suppress a malignant T cell clone that is IL2-dependent. However, infection of normal T cells with HTLV-I leads to IL2-independence for growth in vitro. 37 Similarly, primary ATL cells typically do not proliferate in appropriate short-term cultures with IL2 in vitro, although individual instances may be IL2-responsive. 38, 39 Hence, the role of antibody to mediate IL2 blockade is plausible in a subset of patients.
Seven of 19 patients treated with murine anti-Tac antibody responded to treatment. Six of the responding patients ultimately manifested disease resistance to the therapy and expired. The experience of relapse and disease progression in these responder patients shows that a resistant subpopulation of tumor cells, by whatever mechanism, can overtake the patient, but in no instance was antigen loss a component of that resistance. 4 One patient experienced a durable remission, without relapses in the 5 years since his treatment. To attribute this to a blockade of IL2 in an IL2-dependent tumor, however, the therapy would have had to eliminate a tumor burden estimated at 3 × 10 12 cells in this patient without leaving any IL2-independent sub-population, which appeared unlikely given the propensity of HTLV-I infected cells to evolve towards autonomy. 30, [37] [38] [39] Thus, the response of occasional patients to IL2 suppressive therapy is plausible, but the cure of such patients seemed unlikely by this mechanism alone. Accordingly, we explored other possible explanations for this finding, specifically, the role of an anti-idiotype cascade that could sustain an autogenic reaction against tumor antigen (Tac) by Ab3 antibodies or against its ligand (IL2) by Ab2 antibodies. The appearance of such reactions has been correlated with improved disease prognosis after antibody therapies in other settings. [16] [17] [18] Four years after therapy, analysis of this long-term survivor's circulating antibodies revealed a strong anti-idiotypic HAMA response to MAT and no response against the IgG constant domains. In itself, this marks this patient as unusual in that HAMA responses were observed only in a minority of patients who were treated: ATL patients are immunosuppressed to new antigens, and typically do not make HAMAs. The persistence of HAMA in plasma so long after antigen (MAT) exposure indicates the continued synthesis of immunoglobulin for several years after MAT was removed from circulation. Although the persistence of antigenic MAT in other anatomical locations cannot be formally excluded (indeed, the presence of a HAMA response may lead to increased trapping of MAT on follicular dendritic cells) and the life span of plasma cells in bone marrow has not been definitively established, 40 it was possible that the immune response was maintained by the induction of a network of anti-idiotypic antibodies. 7 Characterization of the HAMA response in plasma screening showed it to be primarily anti-idiotypic (Ab2). Theoretically, the number of antibodies produced at each step of an anti-idiotypic cascade may decrease (Ab2 Ͼ Ab3 Ͼ Ab4). Plasma screening for an Ab3 antibody was tested by RIA against sTac-coated beads. This would sample only a specific subset of potential Ab3s, but the Tac-binding subset is of primary interest in the context of postulated anti-tumor mechanisms. No reactivity was observed at a sensitivity of 1 ng/ml. It was possible that Ab3 antibodies were produced but are now below the detection level of the RIA. To investigate these responses further, we prepared diverse combinatorial antibody libraries representing, as far as is technically possible, the complete repertoire of circulating B cells. Circulating antibodies, produced predominantly by recently activated cells, may not be representative of the immune history of the patient 4 years after treatment since memory B cells will not be detected directly. Combinatorial phage display libraries have been proposed as a means of accessing this B cell compartment. 20 Blood and bone marrow offered the only available anatomical sources of B cells. Although these may or may not provide the optimal source of memory B cells, a subject still debated, 41 peripheral blood was selected as a source of recirculating B cells. Since memory markers remain controversial 42 unsorted PBLs were used. Peripheral blood has the further advantage of containing few, if any plasma cells, which would bias the libraries towards current immune responses by their high immunoglobulin mRNA content.
Screening of the phage display combinatorial libraries for Ab2 antibodies against MAT produced only a single Fab, cc␣Id, an IgG1, antibody specific for the idiotype of MAT. The class-switched ␥1 phenotype, the absence of reactivity among the IgM and IgD libraries, the presence of multiple V gene mutations, and the Fab affinity higher than expected for germline antibodies (Ϸ 10 5 /M) indicate an affinity-selected antibody response against the MAT idiotype. Furthermore, a unique H + L combination was repeatedly selected from the library that otherwise pairs H and L chains randomly. This contrasts with the promiscuity of antibody chain pairings observed in combinatorial antibody library selections against other antigens, 43 suggesting that the particular combination of H + L chains is crucial to binding antigen (MAT idiotype). The cc␣Id thus appears to reflect a dominant monoclonal response in vivo against the anti-Tac idiotype. In contrast, the immune response to the OKT3 monoclonal antibody has been shown to be oligoclonal in most patients, 44 expressing both anti-isotypic and anti-idiotypic antibodies despite immunosuppressive therapy, although one patient, like ours, was shown to make only anti-idiotypic antibodies. 8 As discussed above, anti-idiotypic Ab2 antibodies may mimic antigen (Tac) in ligand binding or may themselves serve as immunogen for the production of Ab3 antibodies that mimic the original Ab1 (MAT) in binding antigen (Figure 1 ). Sequence comparison between cc␣Id and Tac revealed a region of limited homology with Tac at the framework 2/CDR2 junction of the light chain. This region is appropriately exposed in the antibody and could provide the 'antigen' necessary for the induction of the next step in an anti-idiotypic cascade. Chain shuffling experiments using combinatorial libraries have been used to show the promiscuity of heavy and light chain combinations, that is, one heavy chain may be able to pair with a variety of light chains and maintain the same antigen specificity. 43 Yet only a single heavy and light chain pairing was obtained from this library, despite repeated sampling, thus supporting the hypothesis that this Ab2 light chain is critical for idiotype binding. Despite screening of plasma by a sensitive RIA and extensive panning of the combinatorial libraries from this patient, we could find no evidence for the production of Ab3 antibodies recognizing sTac. Additionally, cc␣Id showed no binding to plates coated with purified IL2 by ELISA.
The diversity of the six libraries employed is more than sufficient to recover active antibody responses, 21, 28, 45, 46 but it is uncertain that it could detect clones that are much more rare. An ongoing network-based antibody response is ruled out by the failure to detect IL2-reactive Ab2 or sTac-reactive Ab3 antibodies in the blood or to retrieve IL2-reactive or sTacreactive clones by phage display technology. This observation cannot be considered absolutely informative about earlier responses, now much diminished, but the high complexity of these libraries and their ability to recapitulate the detectable plasma Ab2 response, are at least suggestive that these postulated Ab2 and Ab3 specificities did not occur in this patient. The presence of anti-anti-idiotype antibodies (Ab3) which do not bind sTac was not tested. While these may theoretically play a role in the long-term maintenance of an anti-idiotypic response, 7 they would not be expected to participate in a beneficial therapeutic effect. With the evidence at hand, therefore, there is no basis to support a role for antibody idiotype cascades in mediating the long-term anti-tumor response of anti-Tac antibody therapy in this patient.
A further recent hypothesis related to idiotypy was entertained to explain this patient's remission. After completion of our antibody studies, a report appeared to the effect that treatment with an Ab1 may induce anti-idiotypic Ab2 antibodies that in turn generate not only Ab3 antibodies, but also antianti-idiotype T cell (T3) responses that recognize the original tumor antigen (GA733-2, 17-1A) . 19 The presence of such T3 responses, albeit weak by usual standards of T cell proliferation, correlated positively with tumor regression after antibody therapy. 19 This suggested that antibody immunotherapy may be able to induce T cell responses against an original target antigen. Other protocols immunized actively with preformed Ab2 antibodies of xenogeneic or human origin to the same effect, [47] [48] [49] inducing Ab3 and T3 by single step responses.
We performed this T3 assessment using peripheral T cells from the patient at 7 years post-therapy. The implication of such an autogenic T cell response that also targets a normal protein on activated normal T cells is far from clear. However, T cell stimulation by presented IL2R␣ peptide has been described previously. 50 In our assay, we detected no T3 response, but we also detected no response against the antiTac antibody (Ab1) used in therapy which induced the Ab2 (anti-Id) response. Since the persistent Ab2 anti-idiotype antibody was of a class-switched IgG1 isotype and displayed substantial somatic mutation, hallmarks of T cell help, it would seem necessary that MAT-specific T cells had once been present. The inability to recall this earlier response in vitro suggests that we are too late in the patient's course to detect by this assay a small cohort of memory T cells specific to Ab1 -or specific to Ab2, which would identify T3 cells.
What finally explains the remarkable response in this patient? We are left with the possible IL2 dependence of the patient's tumor, however inadequate this seems to explain complete elimination of the disease, as discussed above. At the time of this patient's treatment the requisite, prospective tests of IL2 dependence were not being routinely conducted to provide an independent assessment. The possibility additionally remains that the time frame of our assays for idiotypic activities of the antibody or T cell immune responses are simply too late to capture the relevant species that once were present. In the absence of positive data, we are unable to confirm the hypothesized role for idiotypy in inducing or maintaining this patient's remarkable response to therapy. But we are also unable at this time point to exclude absolutely a role for idiotypy, particularly T idiotypy. The power of the phage display technology to retrieve prior B cell responses 20 gives us relatively more confidence that the negative data mean there was in fact no Ab3 response that suppressed the Tac-expressing tumor cells. Further studies of responder patients with hematologic malignancies will be needed to address whether the postulated network mechanisms play a therapeutic role in any of these patients.
